atherosclerosis

atherosclerosis
Name	Atherosclerosis
Field	Cardiology, Vascular medicine
Complications	Myocardial infarction, Stroke, Peripheral artery disease
Diagnosis	Clinical evaluation, Imaging
Treatment	Lifestyle modification, Medications, Revascularization

atherosclerosis

Atherosclerosis is a chronic arterial disease characterized by focal intimal lesions that progressively narrow arteries and predispose to thrombotic events. First appreciated in antiquity and described systematically in modern pathology, it underlies major causes of morbidity and mortality including myocardial infarction and ischemic stroke. The disorder implicates interactions among lipid metabolism, inflammation, and vascular cell biology across lifespan.

Overview

Atherosclerosis has been studied by figures linked to major institutions and events such as Rudolf Virchow, William Osler, Royal College of Physicians, John Hunter, Guy's Hospital, St Thomas' Hospital, Harvard Medical School, Johns Hopkins Hospital, Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, University of Oxford, University of Cambridge, Imperial College London, Karolinska Institutet, University of Pennsylvania, Columbia University, Yale University, University of California, San Francisco, Stanford University Medical Center, University of Toronto, McGill University, University of Melbourne, University of Tokyo, Peking University, National Institutes of Health, World Health Organization, Centers for Disease Control and Prevention, American Heart Association, European Society of Cardiology, Royal Society of Medicine, Ludwig Maximilian University of Munich, Charité – Universitätsmedizin Berlin, Mount Sinai Hospital, Guy de Chauliac, Andreas Vesalius, Galen, Hippocrates, William Harvey, James Lind, Edward Jenner, Ignaz Semmelweis, Florence Nightingale, Louis Pasteur, Robert Koch, Alexander Fleming, Ivan Pavlov, Sigmund Freud, Albert Einstein, Marie Curie, Charles Darwin, Alexander Hamilton (physician), Benjamin Rush.

Historic autopsy series and modern epidemiologic cohorts from institutions such as Framingham Heart Study, Dunedin Study, Nurses' Health Study, Health Professionals Follow-up Study, Rotterdam Study, Multi-Ethnic Study of Atherosclerosis, National Health and Nutrition Examination Survey, INTERHEART study have defined population burden and natural history.

Pathophysiology

Lesion development involves endothelial dysfunction, lipid accumulation, inflammatory cell recruitment, smooth muscle migration, and extracellular matrix remodeling. Seminal work referenced by researchers affiliated with Royal Society, National Academy of Sciences, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, Salk Institute, Pasteur Institute, Max Planck Society, Howard Hughes Medical Institute, Wellcome Trust, Bill & Melinda Gates Foundation, Novo Nordisk Foundation, American Association for the Advancement of Science has elucidated mechanisms including low-density lipoprotein retention, oxidation, foam cell formation, and plaque necrosis. Key molecular pathways studied at centers such as Massachusetts Institute of Technology, California Institute of Technology, Broad Institute, Dana-Farber Cancer Institute, Scripps Research implicate cytokines, chemokines, matrix metalloproteinases, and signaling receptors. Animal models developed by groups at Rockefeller University, Weizmann Institute of Science, University of Bern, University of Zurich—including genetically modified mice—help connect genotype to phenotype and therapeutic targets.

Risk factors and epidemiology

Established risk factors defined in cohorts from Framingham Heart Study and public health agencies include hyperlipidemia, hypertension, cigarette smoking, diabetes mellitus, and age. Large-scale studies and consortia such as UK Biobank, Global Burden of Disease Study, EPIC study show variation by geography with high prevalence in populations studied by Centers for Disease Control and Prevention, Public Health England, Health Canada, Australian Institute of Health and Welfare, Chinese Center for Disease Control and Prevention, Indian Council of Medical Research. Socioeconomic and demographic influences have been analyzed by researchers affiliated with World Bank, United Nations, Organisation for Economic Co-operation and Development, Bill & Melinda Gates Foundation. Genetic associations have emerged from efforts by 1000 Genomes Project, International HapMap Project, Global Lipids Genetics Consortium, and groups at Broad Institute, Wellcome Sanger Institute, NIH. Classic risk calculators were developed by teams at Framingham Heart Study, American College of Cardiology, and European Society of Cardiology.

Clinical manifestations and complications

Clinical presentations range from asymptomatic carotid or coronary plaque to acute coronary syndromes, ischemic stroke, mesenteric ischemia, and limb-threatening peripheral artery disease. Treatment algorithms and clinical trials emanating from centers such as Cleveland Clinic, Mayo Clinic, Johns Hopkins Hospital, Mount Sinai Hospital, Brigham and Women's Hospital, Massachusetts General Hospital guide management of complications including myocardial infarction treated in networks like American Heart Association and European Society of Cardiology systems. Complications necessitate multidisciplinary care involving institutions such as Royal College of Surgeons, American College of Cardiology, European Association for Cardio-Thoracic Surgery.

Diagnosis

Noninvasive and invasive diagnostic modalities were refined by investigators at Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Cedars-Sinai Medical Center, Karolinska Institutet, Imperial College London. Techniques include lipid panels, C-reactive protein assays, coronary artery calcium scoring using computed tomography developed with vendors and research groups associated with Siemens Healthineers, GE Healthcare, Philips, and catheter-based angiography pioneered in labs at Barnes-Jewish Hospital and Guy's Hospital. Functional testing and imaging such as stress echocardiography, magnetic resonance imaging developed at National Institutes of Health, European Society of Cardiology, American College of Radiology aid risk stratification.

Prevention and management

Primary and secondary prevention strategies derive from randomized trials conducted by consortia including Danish Study Group, PROVE-IT TIMI Study Group, JUPITER investigators, IMPROVE-IT Investigators, REVEAL Collaboration, and guideline bodies American Heart Association, European Society of Cardiology, National Institute for Health and Care Excellence. Interventions span lifestyle programs studied at Kaiser Permanente, YMCA, Blue Zones research; pharmacotherapy with statins, ezetimibe, PCSK9 inhibitors developed by companies and trial groups such as Pfizer, Novartis, Amgen, Regeneron; antithrombotic regimens tested in trials coordinated by Duke Clinical Research Institute, Beth Israel Deaconess Medical Center. Revascularization procedures—percutaneous coronary intervention and coronary artery bypass grafting—originated in surgical programs at Peter Bent Brigham Hospital, Stanford University Medical Center, Cleveland Clinic, Mayo Clinic.

Research and future directions

Ongoing research by teams at Broad Institute, Wellcome Trust Sanger Institute, NIH, European Research Council, Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative explores gene editing, novel lipid-lowering agents, anti-inflammatory strategies, and regenerative therapies. Large collaborative trials and precision medicine initiatives such as All of Us Research Program, UK Biobank, Million Veteran Program aim to stratify risk and tailor therapies. Emerging technologies developed at MIT, Caltech, Stanford University, ETH Zurich, EPFL include nanomedicine, advanced imaging, and bioengineered vascular grafts; translational pathways involve partnerships with industry players like Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories.

Category:Diseases of arteries